Hims & Hers acquires Eucalyptus for up to $1.15B, expanding globally

Hims & Hers Health, Inc.

Transaction valued up to $1.15B: ~$240M cash upfront, ~$710M deferred over 18 months, up to ~$200M earnouts.
Eucalyptus has ARR >$450M, triple-digit YoY growth in 2025, and served >775,000 customers.
Tim Doyle, Eucalyptus CEO, to become SVP of International at Hims & Hers post-close.
Acquisition expected to close mid-2026, subject to regulatory approvals and customary conditions.
Hims & Hers to finance with existing cash and US operating cash flows; option to settle payments in stock.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Hims & Hers Health, Inc. entered into Securities Sale Deed with the sellers party thereto valued at up to approximately $1,150,000,000 (effective 2026-02-19).

Action: entry
Agreement: asset purchase
Counterparty: the sellers party thereto
Value: up to approximately $1,150,000,000
Effective: 2026-02-19

Exact text from the filing

On February 19, 2026, Hims & Hers Health, Inc. (the “ Company ”), Hims, Inc. (the “ Guarantor ”), and Horizon BidCo Pty Ltd ACN 694 778 375, an Australian proprietary company (the “ Purchaser ”) and wholly-owned subsidiary of the Company, entered into a Securities Sale Deed (the “ Deed ”) with the sellers party thereto (the “ Sellers ”), pursuant to which, among other things, the Sellers agreed to sell and Purchaser agreed to purchase from each Seller (the “ Proposed Acquisition ”) all of the issued capital (the “ Target Equity ”) of EUC Management Pty Ltd ACN 631 013 860 (d/b/a Eucalyptus) (the “ Target ”).

View on SEC.gov

300 material agreements filed in the last 30 days. Browse all material agreements →

Hims & Hers Health, Inc. filing history →

Source: SEC EDGAR

accession 0001773751-26-000010

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.